19 results on '"Heidel, Florian"'
Search Results
2. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
- Author
-
Breccia, Massimo, Bartoletti, Daniela, Bonifacio, Massimiliano, Palumbo, Giuseppe A., Polverelli, Nicola, Abruzzese, Elisabetta, Bergamaschi, Micaela, Tieghi, Alessia, Tiribelli, Mario, Iurlo, Alessandra, Cavazzini, Francesco, Sgherza, Nicola, Binotto, Gianni, Isidori, Alessandro, D’Adda, Mariella, Crugnola, Monica, Bosi, Costanza, Heidel, Florian, Molica, Matteo, Scaffidi, Luigi, Cattaneo, Daniele, Latagliata, Roberto, Auteri, Giuseppe, Lemoli, Roberto M., Fanin, Renato, Russo, Domenico, Aversa, Franco, Cuneo, Antonio, Semenzato, Gianpietro, Catani, Lucia, Cavo, Michele, Vianelli, Nicola, Foà, Robin, and Palandri, Francesca
- Published
- 2019
- Full Text
- View/download PDF
3. Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
- Author
-
Palandri, Francesca, Rossi, Elena, Auteri, Giuseppe, Breccia, Massimo, Paglia, Simona, Benevolo, Giulia, Elli, Elena M., Cavazzini, Francesco, Binotto, Gianni, Tieghi, Alessia, Tiribelli, Mario, Heidel, Florian H., Bonifacio, Massimiliano, Pugliese, Novella, Caocci, Giovanni, Crugnola, Monica, Mendicino, Francesco, D'Addio, Alessandra, Tomassetti, Simona, and Martino, Bruno
- Subjects
POLYCYTHEMIA vera ,HYDROXYUREA ,MULTIVARIATE analysis ,JANUS kinases ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,RESEARCH funding ,NEUROTRANSMITTER uptake inhibitors ,DRUG side effects ,DRUG resistance in cancer cells - Abstract
Simple Summary: The prognostic relevance of a patient achieving complete response to hydroxyurea, the predictors of response, and patients' triggers for switching to ruxolitinib are uncertain. A retrospective, real-world analysis was performed on 563 polycythemia vera patients treated with hydroxyurea for ≥12 months during an observational "PV-NET" Italian study. We investigated factors associated with a complete response to hydroxyurea and outcomes of the 397 poor responders to hydroxyurea according to whether they subsequently received ruxolitinib (n = 114) or continued hydroxyurea (n = 283). The results suggest that many PV patients receive underdosed hydroxyurea, leading to lower response and toxicity rates. In addition, many patients continued hydroxyurea despite a poor clinical or hematological response; however, splenomegaly and other symptoms were the main drivers of an early switch. Better HU management, standardization of the criteria for and timing of responses to HU, and adequate intervention in poor responders should be advised. In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), the predictors of response, and patients' triggers for switching to ruxolitinib are uncertain. In a real-world analysis, we evaluated the predictors of response, their impact on the clinical outcomes of CR to HU, and the correlations between partial or no response (PR/NR) and a patient switching to ruxolitinib. Among 563 PV patients receiving HU for ≥12 months, 166 (29.5%) achieved CR, 264 achieved PR, and 133 achieved NR. In a multivariate analysis, the absence of splenomegaly (p = 0.03), pruritus (p = 0.002), and a median HU dose of ≥1 g/day (p < 0.001) remained associated with CR. Adverse events were more frequent with a median HU dose of ≥1 g/day. Overall, 283 PR/NR patients (71.3%) continued HU, and 114 switched to ruxolitinib. In the 449 patients receiving only HU, rates of thrombosis, hemorrhages, progression, and overall survival were comparable among the CR, PR, and NR groups. Many PV patients received underdosed HU, leading to lower CR and toxicity rates. In addition, many patients continued HU despite a PR/NR; however, splenomegaly and other symptoms were the main drivers of an early switch. Better HU management, standardization of the criteria for and timing of responses to HU, and adequate intervention in poor responders should be advised. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project.
- Author
-
Verstovsek, Srdan, Krečak, Ivan, Heidel, Florian H., De Stefano, Valerio, Bryan, Kenneth, Zuurman, Mike W., Zaiac, Michael, Morelli, Mara, Smyth, Aoife, Redondo, Santiago, Bigan, Erwan, Ruhl, Michael, Meier, Christoph, Beffy, Magali, and Kiladjian, Jean-Jacques
- Subjects
POLYCYTHEMIA vera ,HYDROXYUREA ,ELECTRONIC health records ,BIOMARKERS ,THROMBOSIS - Abstract
Patients with polycythemia vera (PV) are at significant risk of thromboembolic events (TE). The PV-AIM study used the Optum
® de-identified Electronic Health Record dataset and machine learning to identify markers of TE in a real-world population. Data for 82,960 patients with PV were extracted: 3852 patients were treated with hydroxyurea (HU) only, while 130 patients were treated with HU and then changed to ruxolitinib (HU-ruxolitinib). For HU-alone patients, the annualized incidence rates (IR; per 100 patients) decreased from 8.7 (before HU) to 5.6 (during HU) but increased markedly to 10.5 (continuing HU). Whereas for HU-ruxolitinib patients, the IR decreased from 10.8 (before HU) to 8.4 (during HU) and was maintained at 8.3 (after switching to ruxolitinib). To better understand markers associated with TE risk, we built a machine-learning model for HU-alone patients and validated it using an independent dataset. The model identified lymphocyte percentage (LYP), neutrophil percentage (NEP), and red cell distribution width (RDW) as key markers of TE risk, and optimal thresholds for these markers were established, from which a decision tree was derived. Using these widely used laboratory markers, the decision tree could be used to identify patients at high risk for TE, facilitate treatment decisions, and optimize patient management. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
- Author
-
Palandri, Francesca, Breccia, Massimo, Mazzoni, Camilla, Auteri, Giuseppe, Elli, Elena Maria, Trawinska, Malgorzata M., Polverelli, Nicola, Tiribelli, Mario, Benevolo, Giulia, Iurlo, Alessandra, Tieghi, Alessia, Heidel, Florian H., Caocci, Giovanni, Beggiato, Eloise, Binotto, Gianni, Cavazzini, Francesco, Miglino, Maurizio, Bosi, Costanza, Crugnola, Monica, and Bocchia, Monica
- Subjects
MYELOFIBROSIS ,RUXOLITINIB ,POLYCYTHEMIA vera ,LEUKOCYTE count ,PROGNOSTIC models ,REGRESSION analysis - Abstract
Background: Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. Aims and Methods: Prognostic correlates of cytopenic phenotype were explored in 886 ruxolitinib‐treated patients with primary/secondary MF (PMF/SMF) included in the RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 109/L and/or hemoglobin <11/<10 g/dL (males/females) and/or platelets <100 × 109/L. Results: Overall, 407 (45.9%) patients had a cytopenic MF, including 249 (52.4%) with PMF. In multivariable analysis, high molecular risk mutations (p =.04), intermediate 2/high Dynamic International Prognostic Score System (p <.001) and intermediate 2/high Myelofibrosis Secondary to Polycythemia Vera and Essential Thrombocythemia Prognostic Model (p <.001) remained associated with cytopenic MF in the overall cohort, PMF, and SMF, respectively. Patients with cytopenia received lower average ruxolitinib at the starting (25.2 mg/day vs. 30.2 mg/day, p <.001) and overall doses (23.6 mg/day vs. 26.8 mg/day, p <.001) and achieved lower rates of spleen (26.5% vs. 34.1%, p =.04) and symptom (59.8% vs. 68.8%, p =.008) responses at 6 months compared with patients with the proliferative phenotype. Patients with cytopenia also had higher rates of thrombocytopenia at 3 months (31.1% vs. 18.8%, p <.001) but lower rates of anemia (65.6% vs. 57.7%, p =.02 at 3 months and 56.6% vs. 23.9% at 6 months, p <.001). After competing risk analysis, the cumulative incidence of ruxolitinib discontinuation at 5 years was 57% and 38% in patients with cytopenia and the proliferative phenotype (p <.001), whereas cumulative incidence of leukemic transformation was similar (p =.06). In Cox regression analysis adjusted for Dynamic International Prognostic Score System score, survival was significantly shorter in patients with cytopenia (p <.001). Conclusions: Cytopenic MF has a lower probability of therapeutic success with ruxolitinib as monotherapy and worse outcome. These patients should be considered for alternative therapeutic strategies. Cytopenic myelofibrosis has a lower probability of therapeutic success with ruxolitinib as monotherapy and worse outcome. Patients with cytopenic myelofibrosis should be considered for alternative therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Author
-
Palandri, Francesca, Elli, Elena M., Auteri, Giuseppe, Bonifacio, Massimiliano, Benevolo, Giulia, Heidel, Florian H., Paglia, Simona, Trawinska, Malgorzata M., Bosi, Costanza, Rossi, Elena, Tiribelli, Mario, Tieghi, Alessia, Iurlo, Alessandra, Polverelli, Nicola, Caocci, Giovanni, Binotto, Gianni, Cavazzini, Francesco, Beggiato, Eloise, Cilloni, Daniela, and Tatarelli, Caterina
- Subjects
MYELOFIBROSIS ,OVERALL survival ,COVID-19 ,RUXOLITINIB - Abstract
Discussion This study provides epidemiological data on Covid19 infection in MPN patients treated with ruxolitinib, showing that 14.2% of such patients acquired the infection, with an incidence rate of 10.5 × 100 patients-years. Previous studies on Covid19 in MPN patients have included patients regardless of treatment type, with few patients treated with ruxolitinib at the time of the pandemic. Two venous thromboses occurred in Covid19 patients (all hospitalized) (IR 6.7 per 100 patient-years) and 10 thromboses occurred in non-Covid19 patients (IR 1.7 per 100 patient-years, I p i = 0.05). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
7. Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
- Author
-
Passamonti, Francesco, Heidel, Florian H, Parikh, Rohan C, Ajmera, Mayank, Tang, Derek, Nadal, Jose Alberto, Davis, Keith L, and Abraham, Pranav
- Abstract
Aim: To assess real-world ruxolitinib treatment patterns and outcomes in patients diagnosed with primary or secondary myelofibrosis. Materials & methods: Patient medical records were reviewed in six countries. Results: Eligible patients (n = 469) had a mean age of 63.5 years, and most were male (66.5%) with primary myelofibrosis (78.5%). Median duration of ruxolitinib treatment was 13.1 months; 40% of patients initiated treatment at the recommended dose. The Kaplan-Meier estimate of median survival from ruxolitinib initiation was 44.4 months (95% CI, 38.8-50.2 months). Approximately one quarter (23%) of patients continued ruxolitinib after progression. Conclusion: These results suggest an unmet need for more effective treatments for patients with myelofibrosis who failed ruxolitinib. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis.
- Author
-
Palandri, Francesca, Bartoletti, Daniela, Iurlo, Alessandra, Bonifacio, Massimiliano, Abruzzese, Elisabetta, Caocci, Giovanni, Elli, Elena M., Auteri, Giuseppe, Tiribelli, Mario, Polverelli, Nicola, Miglino, Maurizio, Heidel, Florian H., Tieghi, Alessia, Benevolo, Giulia, Beggiato, Eloise, Fava, Carmen, Cavazzini, Francesco, Pugliese, Novella, Binotto, Gianni, and Bosi, Costanza
- Abstract
Background: The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB ≥4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF‐related splenomegaly and symptoms. Its role has not been assessed in correlation with PB. Methods: In 794 chronic‐phase MF patients treated with RUX, we evaluated the impact of baseline percentage of PB on response (spleen and symptoms responses) and outcome (RUX discontinuation‐free, leukemia‐free, and overall survival). Three subgroups were compared: PB‐0 (no PB, 61.3%), PB‐4 (PB 1%‐4%, 33.5%), and PB‐9 (PB 5%‐9%, 5.2%). Results: At 3 and 6 months, spleen responses were less frequently achieved by PB‐4 (P =.001) and PB‐9 (P =.004) compared to PB‐0 patients. RUX discontinuation‐free, leukemia‐free, and overall survival were also worse for PB‐4 and PB‐9 patients (P =.001, P =.002, and P <.001, respectively). Conclusions: Personalized approaches beyond RUX monotherapy may be useful in PB‐4 and particularly in PB‐9 patients. In 794 chronic‐phase myelofibrosis patients treated with ruxolitinib, the impact of the baseline percentage of peripheral blasts (PB) on response and outcome was evaluated. Three subgroups were compared: PB‐0 (no PB, 61.3%), PB‐4 (PB 1%‐4%, 33.5%), and PB‐9 (PB 5%‐9%, 5.2%). At 3 and 6 months, spleen responses were less frequently achieved by PB‐4 (P =.001) and PB‐9 (P =.004) compared to PB‐0 patients; ruxolitinib discontinuation‐free, leukemia‐free, and overall survival were also worse for PB‐4 and PB‐9 patients (P =.001, P =.002, and P <.001, respectively). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
- Author
-
Polverelli, Nicola, Elli, Elena M., Abruzzese, Elisabetta, Palumbo, Giuseppe A., Benevolo, Giulia, Tiribelli, Mario, Bonifacio, Massimiliano, Tieghi, Alessia, Caocci, Giovanni, D'Adda, Mariella, Bergamaschi, Micaela, Binotto, Gianni, Heidel, Florian H., Cavazzini, Francesco, Crugnola, Monica, Pugliese, Novella, Bosi, Costanza, Isidori, Alessandro, Bartoletti, Daniela, and Auteri, Giuseppe
- Subjects
SECONDARY primary cancer ,MYELOFIBROSIS ,SKIN cancer ,MULTIVARIATE analysis - Abstract
Summary: Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non‐melanoma skin cancers (NMSCs). We analyzed the incidence, risk factors and outcome of SPMs in 700 MF patients treated with RUX in a real‐world context. Median follow‐up from starting RUX was 2·9 years. Overall, 80 (11·4%) patients developed 87 SPMs after RUX start. NMSCs were the most common SPMs (50·6% of the cases). Multivariate analysis demonstrated that male sex [hazard ratio (HR): 2·37, 95% confidence interval (95%CI): 1·22–4·60, P = 0·01] and thrombocytosis> 400 × 109/l at RUX start (HR:1·98, 95%CI: 1·10–4·60, P = 0·02) were associated with increased risk for SPMs. Risk factors for NMSC alone were male sex (HR: 3·14, 95%CI: 1·24–7·92, P = 0·02) and duration of hydroxycarbamide and RUX therapy > 5 years (HR: 3·20, 95%CI: 1·17–8·75, P = 0·02 and HR: 2·93, 95%CI: 1·39–6·17, P = 0·005 respectively). In SPMs excluding NMSCs, male sex (HR: 2·41, 95%CI: 1·11–5·25, P = 0·03), platelet > 400 × 109/l (HR: 3·30, 95%CI: 1·67–6·50, P = 0·001) and previous arterial thromboses (HR: 3·47, 95%CI: 1·48–8·14, P = 0·004) were shown to be associated with higher risk of SPMs. While it is reassuring that no aggressive lymphoma was documented, active skin surveillance is recommended in all patients and particularly after prolonged hydroxycaramide therapy; oncological screening should be triggered by thrombocytosis and arterial thrombosis, particularly in males. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
- Author
-
Palandri, Francesca, Breccia, Massimo, Tiribelli, Mario, Bonifacio, Massimiliano, Benevolo, Giulia, Iurlo, Alessandra, Elli, Elena M., Binotto, Gianni, Tieghi, Alessia, Polverelli, Nicola, Martino, Bruno, Abruzzese, Elisabetta, Bergamaschi, Micaela, Heidel, Florian H., Cavazzini, Francesco, Crugnola, Monica, Bosi, Costanza, Isidori, Alessandro, Auteri, Giuseppe, and Forte, Dorian
- Subjects
MYELOFIBROSIS ,PLATELET count ,THERAPEUTICS - Abstract
The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF patients treated with ruxolitinib, we investigated incidence and risk factors for BP and we described outcome according to disease characteristics and treatment strategy. After a median follow-up from ruxolitinib start of 3 years (range 0.1-7.6), 65 (11%) patients transformed to BP during (93.8%) or after treatment. BP incidence rate was 3.7 per 100 patient-years, comparably in primary and secondary MF (PMF/SMF) but significantly lower in intermediate-1 risk patients (2.3 vs 5.6 per 100 patient-years in intermediate-2/high-risk patients, P < .001). In PMF and SMF cohorts, previous interferon therapy seemed to correlate with a lower probability of BP (HR 0.13, P = .001 and HR 0.22, P = .02, respectively). In SMF, also platelet count <150 × 109 /l (HR 2.4, P = .03) and peripheral blasts ≥3% (HR 3.3, P = .004) were significantly associated with higher risk of BP. High-risk category according to dynamic International Prognostic Score System (DIPSS) and myelofibrosis secondary to PV and ET Collaboration Prognostic Model (MYSEC-PM predicted BP in patients with PMF and SMF, respectively. Median survival after BP was 0.2 (95% CI: 0.1-0.3) years. Therapy for BP included hypomethylating agents (12.3%), induction chemotherapy (9.2%), allogeneic transplant (6.2%) or supportive care (72.3%). Patients treated with supportive therapy had a median survival of 6 weeks, while 73% of the few transplanted patients were alive at a median follow-up of 2 years. Progression to BP occurs in a significant fraction of ruxolitinib-treated patients and is associated with DIPSS and MYSEC-PM risk in PMF and SMF, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
- Author
-
Palandri, Francesca, Breccia, Massimo, Bonifacio, Massimiliano, Polverelli, Nicola, Elli, Elena M., Benevolo, Giulia, Tiribelli, Mario, Abruzzese, Elisabetta, Iurlo, Alessandra, Heidel, Florian H., Bergamaschi, Micaela, Tieghi, Alessia, Crugnola, Monica, Cavazzini, Francesco, Binotto, Gianni, Isidori, Alessandro, Sgherza, Nicola, Bosi, Costanza, Martino, Bruno, and Latagliata, Roberto
- Subjects
MYELOFIBROSIS ,PLATELET count ,SALVAGE therapy ,ADVERSE health care events ,PATHOLOGICAL laboratories ,DISEASES ,DISEASE progression ,CHROMOSOMES ,NONPARAMETRIC statistics ,RESEARCH ,HOMOGRAFTS ,HETEROCYCLIC compounds ,CHRONIC myeloid leukemia ,RESEARCH methodology ,RETROSPECTIVE studies ,EVALUATION research ,MEDICAL cooperation ,TREATMENT effectiveness ,SPLEEN diseases ,COMPARATIVE studies ,SURVIVAL analysis (Biometry) ,RED blood cell transfusion ,SPLEEN ,PASSIVE euthanasia - Abstract
Background: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome.Methods: A centralized electronic clinical database was created in 20 European hematology centers, including clinical and laboratory data for 524 patients who received ruxolitinib for myelofibrosis.Results: At 3 years, 40.8% of patients had stopped ruxolitinib. Baseline predictors of drug discontinuation were: intermediate-2-risk/high-risk category (Dynamic International Prognostic Score System), a platelet count <100 ×109 per liter, transfusion dependency, and unfavorable karyotype. At last contact, 268 patients (51.1%) had discontinued therapy, and the median drug exposure was 17.5 months. Fifty patients (18.7%) died while taking ruxolitinib. The reasons for discontinuation in the remaining 218 patients were the lack (22.9%) or loss (11.9%) of a spleen response, ruxolitinib-related adverse events (27.5%), progression to blast phase (23.4%), ruxolitinib-unrelated adverse events (9.2%), and allogeneic transplantation during response (5.1%). The median survival after ruxolitinib was 13.2 months and was significantly better in the 167 patients who discontinued ruxolitinib in chronic phase (27.5 vs 3.9 months for those who discontinued in blast phase; P < .001). No survival differences were observed among patients who discontinued ruxolitinib in chronic phase because of lack of response, loss of response, or ruxolitinib-related adverse events. The use of investigational agents and/or ruxolitinib rechallenge were associated with improved outcome.Conclusions: The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
- Author
-
Palandri, Francesca, Palumbo, Giuseppe A., Abruzzese, Elisabetta, Iurlo, Alessandra, Polverelli, Nicola, Elli, Elena, Bonifacio, Massimiliano, Bergamaschi, Micaela, Martino, Bruno, Tiribelli, Mario, Benevolo, Giulia, Tieghi, Alessia, Sgherza, Nicola, Isidori, Alessandro, Binotto, Gianni, Crugnola, Monica, Heidel, Florian, Cavazzini, Francesco, Bosi, Costanza, and Auteri, Giuseppe
- Subjects
MYELOFIBROSIS ,EARLY diagnosis ,SPLEEN - Abstract
The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
- Author
-
Palandri, Francesca, Catani, Lucia, Bonifacio, Massimiliano, Benevolo, Giulia, Heidel, Florian, Palumbo, Giuseppe A., Crugnola, Monica, Abruzzese, Elisabetta, Bartoletti, Daniela, Polverelli, Nicola, Bergamaschi, Micaela, Tiribelli, Mario, Iurlo, Alessandra, Breccia, Massimo, Cavazzini, Francesco, Tieghi, Alessia, Binotto, Gianni, Isidori, Alessandro, Martino, Bruno, and D'Adda, Mariella
- Subjects
HEMATOLOGY ,ACUTE myeloid leukemia ,MYELOPROLIFERATIVE neoplasms ,ANTINEOPLASTIC agents ,HODGKIN'S disease - Abstract
Summary: Ruxolitinib is a JAK1/2 inhibitor that may control myelofibrosis (MF)‐related splenomegaly and symptoms and can be prescribed regardless of age. While aging is known to correlate with worse prognosis, no specific analysis is available to confirm that ruxolitinib is suitable for use in older populations. A clinical database was created in 23 European Haematology Centres and retrospective data on 291 MF patients treated with ruxolitinib when aged ≥65 years were analysed in order to assess the impact of age and molecular genotype on responses, toxicities and survival. Additional mutations were evaluated by a next generation sequencing (NGS) approach in 69 patients with available peripheral blood samples at the start of ruxolitinib treatment. Compared to older (age 65–74 years) patients, elderly (≥75 years) showed comparable responses to ruxolitinib, but higher rates of drug‐induced anaemia and thrombocytopenia and worse survival. Nonetheless, the ruxolitinib discontinuation rate was comparable in the two age groups. Number and types of molecular abnormalities were comparable across age groups. However, the presence of high molecular risk (HMR) mutations significantly affected survival, counterbalancing the effect of aging. Indeed, elderly patients with <2 HMR mutated genes had a comparable survival to older patients with ≥2 HMR mutations. Given that responses were not influenced by age, older age per se should not be a limitation for ruxolitinib administration. NGS analysis of HMR mutations also confirmed a strong predictive value in elderly patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
- Author
-
Polverelli, Nicola, Palumbo, Giuseppe A., Binotto, Gianni, Abruzzese, Elisabetta, Benevolo, Giulia, Bergamaschi, Micaela, Tieghi, Alessia, Bonifacio, Massimiliano, Breccia, Massimo, Catani, Lucia, Tiribelli, Mario, D'Adda, Mariella, Sgherza, Nicola, Isidori, Alessandro, Cavazzini, Francesco, Martino, Bruno, Latagliata, Roberto, Crugnola, Monica, Heidel, Florian, and Bosi, Costanza
- Abstract
Infections represent one of the major concerns regarding the utilization of ruxolitinib (RUX) in patients with myelofibrosis. With the aim to investigate epidemiology, outcome and risk factors for infections in RUX-exposed patients, we collected clinical and laboratory data of 446 myelofibrosis patients treated with RUX between June 2011 and November 2016 in 23 European Hematology Centers. After a median RUX exposure of 23.5 months (range, 1-56), 123 patients (28%) experienced 161 infectious events (grades 3-4 32%, fatal 9%), for an incidence rate of 17 cases per 100 pts/y. The rate of infections tended to decrease over time: 14% of patients developed the first infection within 6 months, 5% between 6 and 12 months, 3.7% between 12 and 18 months, 3.4% between 18 and 24 months, and 7.9% thereafter (P < .0001). Respiratory tract infections were more frequently observed (81 events, 50%), and bacteria were the most frequent etiological agents (68.9%). However, also viral (14.9%) and fungal infections (2.5%) were observed. In multivariate analysis, previous infectious event (HR 2.54; 95% CI, 1.51-4.28; P = .0005) and high international prognostic score system category (IPSS) (HR 1.53; 95% CI, 1.07-2.20; P = .021) significantly correlated with higher infectious risk. On the contrary, spleen reduction ≥50% from baseline after 3 months of treatment (P = .02) was associated with better infection-free survival. Taken together, these findings reinforce the concept of disease severity as the most important risk factor for infections, and describe, for the first time, that a positive therapeutic effect in reducing splenomegaly may also reduce subsequent infectious complications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
- Author
-
Palandri, Francesca, Tiribelli, Mario, Benevolo, Giulia, Tieghi, Alessia, Cavazzini, Francesco, Breccia, Massimo, Bergamaschi, Micaela, Sgherza, Nicola, Polverelli, Nicola, Crugnola, Monica, Isidori, Alessandro, Binotto, Gianni, Heidel, Florian H., Buccisano, Francesco, Martino, Bruno, Latagliata, Roberto, Spinsanti, Marco, Kallenberg, Lydia, Palumbo, Giuseppe Alberto, and Abruzzese, Elisabetta
- Subjects
HETEROCYCLIC compounds ,MYELOFIBROSIS ,PROGNOSIS ,TREATMENT effectiveness - Abstract
Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate-2/high International Prognostic Score System risk, safety and efficacy data in intermediate-1 patients are limited. We report on 70 intermediate-1 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG-MRT criteria. At 6 months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3 months, ruxolitinib-induced grade 3 anemia and thrombocytopenia occurred in 40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event ≥grade 2. Most (82.6%) patients were still on therapy after a median follow-up of 27 months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.
- Author
-
Jilg, Stefanie, Schwaab, Juliana, Sockel, Katja, Crodel, Carl C., Brueckl, Valeska, Stegelmann, Frank, Jentzsch, Madlen, Sasca, Daniel, Moyses, Margarete, Fuhrmann, Stephan, Gundel, Daniel, Caduc, Madlen, Teichmann, Lino L., Heidel, Florian, Al-Ali, Haifa K., and Petrides, Petro E.
- Subjects
- *
ACTIVIN receptors , *RUXOLITINIB , *SPLEEN , *TREATMENT duration , *THROMBOCYTOPENIA , *MYELOFIBROSIS - Abstract
Recurrent problems of patients with myelofibrosis (MF) are cytopenias, debiliating disease-related symptoms and splenomegaly. Whereas the latter are usually addressed by the JAK1/2 inhibitors ruxolitinib and fedratinib, cytopenias often remain critical. Momelotinib, a JAK1/2 inhibitor recently approved for the treatment of anemic MF patients, was shown to improve anemia via a direct inhibition of activin A receptor type I. In this German-wide, multicenter, retrospective analysis the safety and efficacy profile of momelotinib was evaluated in a real world setting within a cohort of 60 MF patients independent of pre-treatment. The median duration of treatment was 12 weeks. As a new, but manageable safety finding, creatinine increase (CTC°1–2) was detected in 10/60 patients (17%). Interestingly, not only hemoglobin levels increased in 84% of patients, but also platelet values (67%). In the cohort of transfusion-dependent individuals (
n = 38), transfusion requirement improved in 15 patients (39%) with 8 reaching transfusion independency (21%). Transfusion independency was achieved within a median of 4 weeks (range 2–12). Spleen size decreased in 13/53 individuals (25%) with a median response time of 6 weeks. Thereof, 11 patients had been pre-treated with JAK inhibitor(s) (85%). Clinical improvement was detected in 24/51 symptomatic individuals (47%) with a median response time of 4 weeks. 5 patients stopped treatment due to side effects (8%), 6 patients due to a worsening of clinical symptoms (10%). Taken together, the MoReLife analysis identifies momelotinib as potent and safe therapeutic option also for heavily pre-treated cytopenic MF patients under real world conditions. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
17. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
- Author
-
Giuseppe Auteri, Nicola Sgherza, Mario Tiribelli, Lucia Catani, Daniela Bartoletti, Costanza Bosi, Roberto Latagliata, Francesco Cavazzini, Michele Cavo, Franco Aversa, Bruno Martino, Massimiliano Bonifacio, Antonio Cuneo, Gianni Binotto, Giuseppe A. Palumbo, Massimo Breccia, Adalberto Ibatici, Nicola Vianelli, Alessandro Isidori, Monica Crugnola, Gianpietro Semenzato, Alessia Tieghi, Micaela Bergamaschi, Maura Nicolosi, Francesca Palandri, Alessandra Iurlo, Nicola Polverelli, Elisabetta Abruzzese, Giulia Benevolo, Florian H. Heidel, Palandri, Francesca, Palumbo, Giuseppe A, Bonifacio, Massimiliano, Breccia, Massimo, Latagliata, Roberto, Martino, Bruno, Polverelli, Nicola, Abruzzese, Elisabetta, Tiribelli, Mario, Nicolosi, Maura, Bergamaschi, Micaela, Tieghi, Alessia, Iurlo, Alessandra, Sgherza, Nicola, Cavazzini, Francesco, Isidori, Alessandro, Binotto, Gianni, Ibatici, Adalberto, Crugnola, Monica, Heidel, Florian, Bosi, Costanza, Bartoletti, Daniela, Auteri, Giuseppe, Catani, Lucia, Cuneo, Antonio, Aversa, Franco, Semenzato, Gianpietro, Cavo, Michele, Vianelli, Nicola, and Benevolo, Giulia
- Subjects
Male ,Oncology ,Cancer Research ,Ruxolitinib ,medicine.medical_specialty ,Time Factors ,ruxolitinib,myelofibrosis, spleen ,Socio-culturale ,Spleen ,03 medical and health sciences ,0302 clinical medicine ,Hematology ,Internal medicine ,80 and over ,medicine ,Humans ,Myelofibrosis ,Aged ,business.industry ,Aged, 80 and over ,Female ,Middle Aged ,Organ Size ,Rituximab ,Primary Myelofibrosis ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,business ,030215 immunology ,medicine.drug - Abstract
NA
- Published
- 2018
18. Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
- Author
-
Elisabetta Abruzzese, Nicola Vianelli, Massimiliano Bonifacio, Elena Maria Elli, Giulia Benevolo, Antonio Cuneo, Francesca Palandri, Monica Crugnola, Nicola Sgherza, Robin Foà, Mario Tiribelli, Massimo Breccia, Alessandra Iurlo, Daniela Bartoletti, Alessandro Isidori, Mauro Krampera, Giuseppe A. Palumbo, Alessia Tieghi, Nicola Polverelli, Roberto M. Lemoli, Giuseppe Auteri, Gianni Binotto, Florian H. Heidel, Micaela Bergamaschi, Michele Cavo, Roberto Latagliata, Bruno Martino, Francesco Cavazzini, Daniele Cattaneo, Costanza Bosi, Palandri, Francesca, Palumbo, Giuseppe A, Abruzzese, Elisabetta, Iurlo, Alessandra, Polverelli, Nicola, Elli, Elena, Bonifacio, Massimiliano, Bergamaschi, Micaela, Martino, Bruno, Tiribelli, Mario, Benevolo, Giulia, Tieghi, Alessia, Sgherza, Nicola, Isidori, Alessandro, Binotto, Gianni, Crugnola, Monica, Heidel, Florian, Cavazzini, Francesco, Bosi, Costanza, Auteri, Giuseppe, Cattaneo, Daniele, Foà, Robin, Lemoli, Roberto M, Cuneo, Antonio, Krampera, Mauro, Bartoletti, Daniela, Cavo, Michele, Vianelli, Nicola, Breccia, Massimo, and Latagliata, Roberto
- Subjects
Male ,Cancer Research ,Ruxolitinib ,EARLY PMF ,MYELOFIBROSIS ,OVERT PMF ,RUXOLITINIB ,Heart disease ,0302 clinical medicine ,Essential ,Diagnosis ,80 and over ,Thrombocythemia ,Molecular Targeted Therapy ,Aged, 80 and over ,Hematology ,General Medicine ,Organ Size ,Middle Aged ,Neoplasm Proteins ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Toxicity ,Female ,Thrombocythemia, Essential ,medicine.drug ,Cohort study ,Adult ,medicine.medical_specialty ,Adolescent ,Anemia ,Socio-culturale ,Antineoplastic Agents ,World Health Organization ,Diagnosis, Differential ,03 medical and health sciences ,Internal medicine ,Nitriles ,medicine ,Humans ,Myelofibrosis ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,business.industry ,Clinical Laboratory Techniques ,Retrospective cohort study ,Early Diagnosis ,Janus Kinase 2 ,Primary Myelofibrosis ,Pyrazoles ,Spleen ,medicine.disease ,Pyrimidines ,Differential ,Differential diagnosis ,business ,030215 immunology - Abstract
The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.
- Published
- 2019
19. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
- Author
-
Alessia Tieghi, Massimo Breccia, Antonio Cuneo, Alessandro Isidori, Giulia Benevolo, Giuseppe A. Palumbo, Francesco Buccisano, Michele Cavo, Marco Spinsanti, Elisabetta Abruzzese, Nicola Sgherza, Gianni Binotto, Francesca Palandri, Micaela Bergamaschi, Massimiliano Bonifacio, Mario Tiribelli, Bruno Martino, Florian H. Heidel, Lydia Kallenberg, Nicola Vianelli, Roberto Latagliata, Francesco Cavazzini, Nicola Polverelli, Luigi Scaffidi, Monica Crugnola, Palandri, Francesca, Tiribelli, Mario, Benevolo, Giulia, Tieghi, Alessia, Cavazzini, Francesco, Breccia, Massimo, Bergamaschi, Micaela, Sgherza, Nicola, Polverelli, Nicola, Crugnola, Monica, Isidori, Alessandro, Binotto, Gianni, Heidel, Florian H., Buccisano, Francesco, Martino, Bruno, Latagliata, Roberto, Spinsanti, Marco, Kallenberg, Lydia, Palumbo, Giuseppe Alberto, Abruzzese, Elisabetta, Scaffidi, Luigi, Cuneo, Antonio, Cavo, Michele, Vianelli, Nicola, and Bonifacio, Massimiliano
- Subjects
Male ,Ruxolitinib ,Pediatrics ,medicine.medical_specialty ,Cancer Research ,System risk ,Constitutional symptoms ,Anemia ,ruxolitinib ,Socio-culturale ,myelofibrosis ,Prognostic score ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,intermediate-1 risk ,IPSS ,MF ,Hematology ,Oncology ,Nitriles ,medicine ,Humans ,Adverse effect ,Myelofibrosis ,Aged ,business.industry ,Myelofibrosi ,General Medicine ,Prognosis ,medicine.disease ,Pyrimidines ,Treatment Outcome ,Primary Myelofibrosis ,030220 oncology & carcinogenesis ,Pyrazoles ,Female ,business ,030215 immunology ,medicine.drug - Abstract
Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate-2/high International Prognostic Score System risk, safety and efficacy data in intermediate-1 patients are limited. We report on 70 intermediate-1 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG-MRT criteria. At 6 months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3 months, ruxolitinib-induced grade 3 anemia and thrombocytopenia occurred in 40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event ≥grade 2. Most (82.6%) patients were still on therapy after a median follow-up of 27 months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.